Minerva Neurosciences, Inc. (NERV)
$2.62
+0.03
(+1.27%)▲
Performance
- $2.60$2.71$2.62
0.76%
Downside
Day's Volatility :4.16%
Upside
3.42%
- $2.26$13.49$2.62
13.74%
Downside
52 Weeks Volatility :83.25%
Upside
80.58%
Returns
| Period | Minerva Neurosciences, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -16.45% | 4.9% | 0.0% |
6 Months | 1.97% | 5.8% | 0.0% |
1 Year | -58.36% | 17.8% | 0.0% |
3 Years | -77.67% | 20.1% | -20.6% |
Highlights
Market Capitalization | 18.9M |
Book Value | - $6.36 |
Earnings Per Share (EPS) | -4.4 |
PEG Ratio | 0.0 |
Wall Street Target Price | 5.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -28.88% |
Return On Equity TTM | -675.09% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | -16.8M |
EBITDA | -26.2M |
Diluted Eps TTM | -4.4 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.26 |
EPS Estimate Next Year | -2.03 |
EPS Estimate Current Quarter | -0.97 |
EPS Estimate Next Quarter | -0.73 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 90.84%
Technicals Summary
Sell
Neutral
Buy
Minerva Neurosciences, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Minerva Neurosciences, Inc. | 0.0% | 1.97% | -58.36% | -77.67% | -93.09% |
 Regeneron Pharmaceuticals, Inc. | -11.82% | 7.63% | 22.08% | 84.17% | 257.49% |
 Novo Nordisk A/s | -12.08% | -8.57% | 27.88% | 136.23% | 343.21% |
 Alnylam Pharmaceuticals, Inc. | 7.18% | 75.52% | 50.82% | 35.89% | 250.13% |
 Vertex Pharmaceuticals Incorporated | -3.21% | 11.53% | 27.71% | 156.23% | 163.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Minerva Neurosciences, Inc. | NA | NA | 0.0 | -2.26 | -6.75 | -0.29 | NA | -6.36 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Minerva Neurosciences, Inc. | Sell | $18.9M | -93.09% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 257.49% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 343.21% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 250.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.62% | 32.84 | -4.74% |
Insights on Minerva Neurosciences, Inc.
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 50.8% return, outperforming this stock by 109.2%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 35.9% return, outperforming this stock by 113.6%
Institutional Holdings
Federated Hermes Inc
19.32%Vanguard Group Inc
3.60%Renaissance Technologies Corp
2.40%UBS O'Connor LLC
1.43%BlackRock Inc
1.04%Geode Capital Management, LLC
0.79%
Company Information
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Organization | Minerva Neurosciences, Inc. |
Employees | 9 |
CEO | Dr. Remy Luthringer Ph.D. |
Industry | Health Technology |
Discover More
Eagle Pharmaceuticals Inc.
$2.62
+1.27%
Rumbleon Inc
$2.62
+1.27%
Olaplex Holdings, Inc.
$2.62
+1.27%
Bluebird Bio, Inc.
$2.62
+1.27%
Generation Income Properties Inc
$2.62
+1.27%
Ondas Holdings Inc
$2.62
+1.27%
Nuveen Credit Strat Incm
$2.62
+1.27%
Touchstone Climate Transition Etf
$2.62
+1.27%
Atlas Lithium Corp
$2.62
+1.27%